Investigating the Acute Effects of THC on Functional Brain Systems (FIX)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine whether THC, the main psychoactive ingredient in cannabis, affects functional brain systems underlying memory and reward.
| Condition | Intervention | Phase |
|---|---|---|
|
Reward Tetrahydrocannabinol Endocannabinoids Memory Magnetic Resonance Imaging |
Drug: Delta9-tetrahydrocannabinol (THC) |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Pharmacokinetics/Dynamics Study Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Basic Science |
| Official Title: | Investigating the Acute Effects of THC on Functional Brain Systems |
- The main study parameter is the blood oxygen level dependent (BOLD) signal. [ Time Frame: 4 months ] [ Designated as safety issue: No ]
- Behavioral parameters (two VAS questionnaires) [ Time Frame: 4 months ] [ Designated as safety issue: No ]
- Cerebral blood flow (ASL) [ Time Frame: 4 months ] [ Designated as safety issue: No ]
- Concentration of plasma THC and its main metabolites [ Time Frame: 4 months ] [ Designated as safety issue: No ]
- Performance on neuropsychological tests [ Time Frame: 4 months ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 12 |
| Study Start Date: | April 2008 |
| Study Completion Date: | September 2008 |
| Primary Completion Date: | September 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: A
Inhalation of THC, using a Volcano vaporizer
|
Drug: Delta9-tetrahydrocannabinol (THC)
inhalation of 6 mg liquid THC, vaporized by means of a Volcano vaporizer
Other Name: dronabinol, marinol, THC, tetrahydrocannabinol
|
|
Placebo Comparator: B
Inhalation of vehicle, using a Volcano vaporizer
|
Drug: Delta9-tetrahydrocannabinol (THC)
inhalation of 6 mg liquid THC, vaporized by means of a Volcano vaporizer
Other Name: dronabinol, marinol, THC, tetrahydrocannabinol
|
Detailed Description:
Cannabis is by far the most frequently used illicit drug worldwide and has significant effects on memory. Further, cannabis has an addictive potential. These effects are mediated by an action of THC, the main psychoactive ingredient of cannabis, on cannabinoid CB1 receptors. These receptors are particularly highly expressed in brain regions involved in memory and reward. Therefore, in this study we will investigate the acute effects of THC on functional brain systems underlying memory and reward. We will visualize these effects using the latest non-invasive imaging technique: pharmacological MRI (phMRI).
Eligibility| Ages Eligible for Study: | 18 Years to 45 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- History of mild cannabis use for at least one year (<1/week and ≥ 4/year)
- History without psychotic experiences after cannabis use
- Age between 18 and 45 years
- Right-handedness, assessed with the Edinburgh Handedness Inventory
- Written informed consent of the subject
Exclusion Criteria:
- Any clinical significant abnormality of any clinical laboratory test, including urinary drug screening
- Impaired physical health evaluated by medical history, physical (including neurological) examination and screening laboratory tests
- History of clinically significant psychiatric or neurological illness
- History of clinically significant psychiatric or neurological illness in first- or second-degree relatives
- History of alcohol and/or drug abuse (DSM-IV criteria)
- Body Mass Index (B.M.I.) <18 kg/m2 or >28 kg/m2
- Paranoid ideation or psychoticism on SCL-90
- Any subject who received any investigational medication within 90 days prior to the start of the study or who is scheduled to receive an investigational drug
- The use of any medication within three weeks prior to the start of the study, except for paracetamol
- Positive HIV or Hepatitis B/C test
- Blood donation within 3 months before the start of the study
- Claustrophobia
- Metal objects in or around the body (braces, pacemaker, metal fragments)
Contacts and Locations| Netherlands | |
| University Medical Center Utrecht | |
| Utrecht, Netherlands, 3584CX | |
| Principal Investigator: | Nick Ramsey, Professor | UMC Utrecht |
More Information
No publications provided by UMC Utrecht
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Prof. N.F. Ramsey, UMC Utrecht |
| ClinicalTrials.gov Identifier: | NCT00628706 History of Changes |
| Other Study ID Numbers: | THC-phMRI-01 |
| Study First Received: | February 24, 2008 |
| Last Updated: | February 17, 2009 |
| Health Authority: | Netherlands: Dutch Health Care Inspectorate Netherlands: Medical Ethics Review Committee (METC) Netherlands: The Central Committee on Research Involving Human Subjects (CCMO) |
Keywords provided by UMC Utrecht:
|
tetrahydrocannabinol memory reward magnetic resonance imaging endocannabinoids |
Additional relevant MeSH terms:
|
Tetrahydrocannabinol Hallucinogens Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses |
Psychotropic Drugs Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents |
ClinicalTrials.gov processed this record on May 23, 2013